Ed Silverman from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 8 days ago STAT+: U.K. lawmaker wants regulators to probe pharma companies over ‘misleading’ Covid-19 vaccines statements - 8 days ago STAT+: Pharmalittle: We’re reading about FDA morale, pharma removing DEI goals, and more - 8 days ago STAT+: Pharmalittle: We’re reading about fears of a Trump-inspired brain drain, Ozempic’s effect on drinking, and more - 9 days ago STAT+: As Trump pauses enforcement of an anti-bribery law, will pharma engage in bad behavior? - 10 days ago STAT+: Pharmalittle: We’re reading about pharma silence on Trump moves, lawmakers eyeing PBMs again, and more - 10 days ago STAT+: Pharmalittle: We’re reading about a China probe of AstraZeneca, a ‘troubling’ Super Bowl ad, and more - 16 days ago STAT+: Pharmalittle: We’re reading about an FDA hold on an Amgen obesity drug, imported Canadian drugs, and more - 17 days ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Pharmalittle: We’re reading about Medicare plans to negotiate obesity-drug prices, a Novartis 340B lawsuit, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about FDA commish’s parting thoughts, a warning on RSV shots, and more - about 2 months ago STAT+: Pharmalittle: We’re reading about FDA guidance on AI, meds releasing ‘forever chemicals,’ and more - about 2 months ago STAT+: Pharmalittle: We’re reading about Novo and GLP-1 compounding, Paxlovid and long Covid, and more - about 2 months ago STAT+: Pharmalittle: We’re reading about a Merck deal for an obesity pill, a departing FDA official, and more - 2 months ago STAT+: Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal - 2 months ago STAT+: Feds threaten Sanofi with sanctions over plan to change payment terms for a federal drug discount program - 2 months ago STAT+: South African regulator decides Vertex provides sufficient access to CF drugs, angering activists - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Pharmalittle: We’re reading about Editas layoffs, House Republicans probing CVS, and more - 2 months ago STAT+: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players, report finds - 2 months ago STAT+: Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more - 2 months ago STAT+: European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about menopause treatments, Novo plans for Wegovy in India, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a former Trump FDA chief criticizing RFK Jr., a radiopharmaceuticals talent shortage, and more - 3 months ago STAT+: Big restaurant chains get an ‘F’ for antibiotic use in their meat supplies - 3 months ago STAT+: Bristol Myers is the latest drug company to sue HHS over payment terms for 340B hospitals - 3 months ago STAT+: Pharmalittle: We’re reading about Medicare obesity drug coverage, a first-of-its-kind 340B analysis, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about picking an FDA chief, a menopause film controversy, and more - 3 months ago STAT+: A documentary about menopause has ‘misinformation’ and shouldn’t be used to educate docs, critics say - 3 months ago STAT+: Pharmalittle: We’re reading about Trump and tariff worries, PBM rules in New York, and more - 3 months ago STAT+: The health care industry is girding for Trump’s tariffs —and pushing hard for carveouts - 3 months ago STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more - 3 months ago STAT+: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds - 3 months ago STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Pharmalittle: We’re reading about FDA plans to ban a cold med; Eisai Alzheimer’s drug sales, and more - 4 months ago STAT+: AstraZeneca says China has detained a senior executive - 4 months ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 4 months ago STAT+: Pharmalittle: We’re reading about compounded Wegovy, pharmacies suing GoodRx, and more - 4 months ago STAT+: Pharmacies sue GoodRx and PBMs over ‘illegal’ reimbursement fees - 4 months ago STAT+: Pharmalittle: We’re reading about Medicaid coverage of obesity drugs, a death in a sickle cell trial, and more - 4 months ago STAT+: Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 4 months ago STAT+: To mitigate drug shortages, a new study suggests looking at Canada - 4 months ago STAT+: Two generic drugmakers to pay $49 million to settle price-fixing charges - 4 months ago STAT+: Teva fined $503 million for disparaging a rival and using patents to thwart competition - 4 months ago STAT+: Helsinki Declaration says researchers must disclose trial results on a timely basis - 4 months ago
2	Tara Bannow STAT News Reporter @statnews. healthcarejournalism	STAT+: The health care industry is girding for Trump’s tariffs —and pushing hard for carveouts - 3 months ago
3	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 4 months ago
4	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 4 months ago
5	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 4 months ago
6	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 4 months ago